UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                -----------------

                                    FORM 8-K

                                -----------------

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

                        Date of report: November 1, 2007

                           THERAGENICS CORPORATION(R)

               (Exact name of registrant as specified in charter)

          Delaware                   000-15443                 58-1528626
   (State of incorporation)    (Commission File Number)      (IRS Employer
                                                           Identification No.)

                           5203 Bristol Industrial Way
                              Buford, Georgia 30518
               (Address of principal executive offices / Zip Code)

                                 (770) 271-0233
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))




Item 2.02.    Results of Operations and Financial Condition.

     On November 1, 2007, Theragenics Corporation (the "Company") issued a press
release regarding its consolidated financial results for the quarter ended
September 30, 2007. The Company's press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.

     The information in this Current Report on Form 8-K and the Exhibit attached
hereto shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, regardless of
any general incorporation language in such filing.



                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                 Theragenics Corporation

                                                      (Registrant)

                                                 Dated: November 1, 2007


                                                 By: /s/ M. Christine Jacobs
                                                     -----------------------
                                                       M. Christine Jacobs
                                                     Chief Executive Officer



                                  EXHIBIT INDEX

Exhibit No.    Description

99.1           Press Release, dated November 1, 2007 of Theragenics Corporation.